RSS | Login | Register

JANUVIA

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare JANUVIA to:

Generic Name for JANUVIA

Sitagliptin (as phosphate) 25mg, 50mg, 100mg; tabs.

Legal Classification:

Pharmacological Class for JANUVIA

Dipeptidyl peptidase-4 inhibitor.

Manufacturer of JANUVIA

Merck & Co., Inc.

Indications for JANUVIA

Adjunct to diet and exercise in type 2 diabetes, as monotherapy or combination therapy (see literature).

Adult dose for JANUVIA

100mg once daily. Renal insufficiency: CrCl ≥30–50mL/min: 50mg once daily; CrCl<30mL/min or on dialysis: 25mg once daily.

Children's dosing for JANUVIA

<18yrs: not recommended.

Contraindications for JANUVIA

Not for the treatment of type 1 diabetes or diabetic ketoacidosis.

Warnings/Precautions for JANUVIA

Monitor renal function before starting therapy, then periodically. Severe hepatic insufficiency. Pregnancy (Cat.B). Nursing mothers.

Interactions for JANUVIA

Concomitant sulfonylurea: may need lower dose of sulfonylurea to reduce risk of hypoglycemia. Monitor digoxin.

Adverse Reactions for JANUVIA

Nasopharyngitis, upper respiratory tract infection, headache; hypersensitivity reactions (eg, anaphylaxis, angioedema, Stevens-Johnson syndrome), discontinue if occur.

How is JANUVIA supplied?

Tabs—30, 90, 100

Related Disease:

Diabetes mellitus~hyperglycemic agents

Finesse insulin patch-pen approved for use with Novolog

July 26, 2010

The FDA has approved Finesse, an insulin patch-pen from Calibra Medical, for up to three-day use with Novolog (insulin aspart, from Novo Nordisk).

Phase 2b study of ARC-4558 for painful diabetic neuropathy (PDN)

July 20, 2010

Arcion Therapeutics announced positive results from a Phase 2b, double-blind, randomized, placebo-controlled clinical trial of ARC-4558 (clonidine HCl 0.1% topical gel) in patients with painful diabetic neuropathy (PDN).

FDA conducts safety review of cancer risk with angiotensin receptor blockers (ARBs)

July 15, 2010

A recently published meta-analysis combining cancer-related findings from several clinical trials is suggesting that angiotensin receptor blockers (ARBs) may be associated with a small increased risk of cancer.